Inserm Transfert Initiative

Johnson & Johnson forms Ebola vaccine development consortia

Monday, January 19, 2015

Johnson & Johnson has formed a consortia with leading global research institutions and non-government organizations to work in conjunction with Janssen Pharmaceutical to accelerate the development of its Ebola vaccine regimen. The Innovative Medicines Initiative (IMI) plans to award these consortia grants totaling more than $116 million from the Ebola+ program to support the development, manufacturing and patient education for the vaccine regimen.

[Read More]

TxCell, Ferring collaborate on Ovasave

Monday, January 5, 2015

TxCell, a biotechnology company developing personalized T cell immunotherapies for severe chronic inflammatory and autoimmune diseases, is collaborating with Ferring International Center on the development of TcCell’s lead product Ovasave for the treatment of inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis. TxCell, a spin-off of Inserm (France’s National Institute for Health and Medical Research) is located in the Sophia Antipolis technology park, Nice, France.

[Read More]

Boston Scientific enrolls first patients in NECTAR-HF trial

Friday, September 30, 2011

Boston Scientific has enrolled the first patients in its NECTAR-HF (neural cardiac therapy for heart failure) clinical trial.  NECTAR-HF is a prospective, randomized, international clinical feasibility study designed to assess preliminary safety and efficacy of chronic vagal nerve stimulation in heart failure patients.  The study will evaluate 96 patients with vagal nerve stimulator implants at multiple centers in Europe.

[Read More]